Holen Sie sich die Stockscreener-App
0.9949
7.88%
-0.0851
Vorhandelsmarkt:
.96
-0.0349
-3.51%
Schlusskurs vom Vortag:
$1.08
Offen:
$1.02
24-Stunden-Volumen:
2.57M
Relative Volume:
2.34
Marktkapitalisierung:
$3.67M
Einnahmen:
$735.20K
Nettoeinkommen (Verlust:
$-9.70M
KGV:
-0.00228
EPS:
-435.729
Netto-Cashflow:
$-9.80M
1W Leistung:
-5.25%
1M Leistung:
-73.40%
6M Leistung:
-98.96%
1J Leistung:
-99.51%
1-Tages-Spanne:
$0.9647
$1.045
1-Wochen-Bereich:
$0.95
$1.1495
52-Wochen-Spanne:
$0.911
$270.00
Onconetix Inc Stock (ONCO) Company Profile
Firmenname
Onconetix Inc
Sektor
Branche
Telefon
513-620-4101
Adresse
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.9949 | 4.02M | 735.20K | -9.70M | -9.80M | -435.73 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onconetix Inc Aktie (ONCO) Neueste Nachrichten
Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
ONCO News | ONCONETIX INC (NASDAQ:ONCO) - ChartMill
Onconetix Company Profile & Introduction - Moomoo
OnconetixRegisters Up To 100 Million Shares For Resale By Keystone Capital PartnersSEC Filing - TradingView
ONCO Stock Price, Quote & Chart - ChartMill
Onconetix (ONCO) files S-1 for 100M-share Keystone equity line amid going-concern risks - Stock Titan
Onconetix approves 1-for-10 reverse stock split effective May 21 - Investing.com UK
Humanoid robot maker Realbotix posts $442K income, plans Nasdaq listing - Stock Titan
ONCO - Finviz
Number of shareholders of Onconetix Inc – FWB:J4T - TradingView
Number of shareholders of Onconetix Inc – GETTEX:A42ANX - TradingView
Pretax income of Onconetix Inc – GETTEX:A42ANX - TradingView
Onconetix Inc (ONCO) Stock Price, Quote, News & History - Benzinga
Onconetix reverse split 10-to-1, aimed at Nasdaq $1 bid rule - Stock Titan
Onconetix Sets 1-for-10 Reverse Stock Split Effective - TipRanks
Onconetix (ONCO) enacts 1-for-10 reverse split to support Nasdaq listing - Stock Titan
What's going on in today's session - ChartMill
Which stocks are most active on Tuesday? - ChartMill
Onconetix approves 1-for-10 reverse stock split effective May 21 By Investing.com - Investing.com Australia
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Realbotix Provides Update on Nasdaq Listing - Investing News Network
Onconetix, Inc. announces 1-for-10 reverse stock split - marketscreener.com
Onconetix: Split Intended to Enable Co to Maintain Compliance With Minimum Bid Price Requirement of $1/Shr of Common Stk for Continued Listing on Nasdaq Cap Market >ONCO - Moomoo
Realbotix provides update on Nasdaq listing - marketscreener.com
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
Onconetix (ONCO) stock surges over 23% overnight: Why is it moving? - MSN
Onconetix shares jump 23.65% after clinical study boosts confidence in prostate cancer test Proclarix. - Pluang
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? - Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed ... - Post Register
Onconetix Advances Proclarix Clinical Validation and Market Expansion - TipRanks
Onconetix (ONCO) highlights new Proclarix studies and U.S. PRIME trial - Stock Titan
Onconetix Reports Q1 2026 Progress: Proclarix® Validated in Peer-Reviewed Studies, U.S. PRIME Study Launched, and European Expansion Continues 1 - Minichart
Onconetix reports Proclarix peer-reviewed data and launches U.S. PRIME validation study with Labcorp - TradingView
Onconetix, Inc. Q1 2026 Financial Report: Key Risks, Market Strategies, and Forward-Looking Statements - Minichart
Onconetix's Proclarix advances with new studies and U.S. validation study launch, expanding in Europe. - Pluang
Onconetix reports Q1 progress for prostate cancer test Proclarix By Investing.com - Investing.com India
ONCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Onconetix Reports Two Proclarix Publications and U.S. Validation Study in Q1 2026 - geneonline.com
Onconetix reports Q1 progress for prostate cancer test Proclarix - Investing.com
Onconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with Labcorp - Quiver Quantitative
Blood test aims to cut unnecessary prostate biopsies, now in U.S. study - Stock Titan
Onconetix Reports Q1 2026 Progress at Proteomedix AG, - GlobeNewswire
Onconetix, Inc. 1Q 2026: Revenue $21.46K, EPS ($6.71) — 10-Q Summary - TradingView
Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Onconetix (NASDAQ: ONCO) posts Q1 loss, warns on going concern amid Realbotix deal - Stock Titan
Onconetix, Inc. (ONCO) Eps Diluted (TTM) - Zacks Investment Research
How to Buy Onconetix (ONCO) Stock in Canada - Moomoo
[EFFECT] Onconetix, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Onconetix (ONCO) registers 25M shares for resale under Keystone ELOC - Stock Titan
Finanzdaten der Onconetix Inc-Aktie (ONCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Onconetix Inc-Aktie (ONCO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Apr 17 '26 |
Buy |
0.73 |
34,636 |
25,284 |
177,821 |
| HRT FINANCIAL LP | 10% Owner |
Apr 20 '26 |
Sale |
0.75 |
94,462 |
70,846 |
83,359 |
| HRT FINANCIAL LP | 10% Owner |
Apr 16 '26 |
Sale |
0.73 |
53,867 |
39,323 |
143,185 |
| HRT FINANCIAL LP | 10% Owner |
Apr 15 '26 |
Buy |
0.76 |
92,554 |
70,341 |
197,052 |
| HRT FINANCIAL LP | 10% Owner |
Apr 14 '26 |
Buy |
0.77 |
74,350 |
57,250 |
104,498 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):